v3.26.1
STOCKHOLDERS’ EQUITY (Tables)
 12 Months Ended
Mar. 31, 2026
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF RESTRICTED STOCK AWARDS

A summary of the Company’s restricted stock unit awards for the years ended March 31, 2026 and March 31, 2025 is as follows:

  

Number Of

Shares

  

Weighted

Average Grant

Date Fair

Value

 
         
Unvested as of March 31, 2024   30,945   $139.60 
Granted   -    - 
Vested   (12,240)   137.20 
Forfeited   (440)   229.60 
Unvested as of March 31, 2025   18,265   $139.40 
Granted   -    - 
Vested   (8,630)   150.26 
Forfeited   (150)   137.40 
Unvested as of March 31, 2026   9,485   $129.41 
SCHEDULE OF FAIR VALUE OF OPTION

The following was utilized to calculate the fair value of options on the date of grant:

 

  

March 31,

2026

  

March 31,

2025

 
Risk -free interest rate   3.7-4.2%   3.6-4.4%
Expected volatility (Beyond Air)   91.6-106.2%   83.6-89.9%
Expected volatility (Beyond Cancer)   N/A%   N/A%
Expected volatility (NeuroNos)   95.0%   95.0%
Dividend yield   0%   0%
Expected terms (in years)   6.25    6.25 
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE

The following summarizes the components of stock-based compensation expense which included stock options and restricted stock for the years ended March 31, 2026 and March 31, 2025 (in thousands):

 

   2026   2025 
   Year Ended 
   March 31, 
   2026   2025 
         
Research and development  $1,153   $471 
General and administrative   4,129    8,675 
           
Total stock-based compensation expense  $5,282   $9,146 
SUMMARY OF OUTSTANDING WARRANTS

A summary of the Company’s outstanding warrants as of March 31, 2026 is as follows:

 

Warrant Holders 

Number of

Warrants

  

Exercise

Price

  

Intrinsic Value

(in thousands)

  

Date of

Expiration

                
NitricGen agreement   4,000   $138.00   $-   January 2028
Avenue agreement   11,693   $7.59    -   June 2028
March 2024 raise   481,936   $45.00    -   March 2027
Avenue extension agreement   5,000   $25.60    -   June 2029
September 2024 equity offering   555,229   $7.59    -   September 2029
September 2024 debt instrument   1,270,796   $1.95    -   September 2029 / November 2030
September 2025 inducement   719,562   $2.21    -   September 2030
January 2026 equity offering   3,930,818   $1.147    -   January 2031
Subtotal   6,979,034   $5.05   $-    
                   
Pre-funded warrants (Sep-2024 offering)   220,006   $0.002   $151   September 2029
Pre-funded warrants (Jan-2026 offering)   2,142,613   $0.0001   $1,479   January 2031
Total   9,341,653   $3.773   $1,630    
2013 Beyond Air Equity Incentive Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF OPTION ACTIVITY FOR NEURONOS

A summary of the change in stock options for the years ended March 31, 2026 and March 31, 2025 is as follows:

 

  

Number

Of

Options

  

Weighted

Average

Exercise

Price–-

Options

  

Weighted

Average

Remaining

Contractual

Life-

Options

  

Aggregate

Intrinsic

Value

(thousands)

 
                 
Options outstanding as of March 31, 2024   566,645   $88.39    8.0   $760 
Granted   227,550    6.06           
Exercised   -    -           
Forfeited   (54,976)   61.74           
Options outstanding as of March 31, 2025   739,219   $9.34    7.9   $- 
Granted   94,800    0.92           
Exercised   -    -           
Forfeited   (77,270)   1.95           
Outstanding as of March 31, 2026   756,749   $1.82    7.2   $- 
Exercisable as of March 31, 2026   497,591   $1.95    6.3   $- 
2021 Beyond Cancer Ltd Equity Incentive Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF OPTION ACTIVITY FOR NEURONOS

A summary of the change in stock options for Beyond Cancer for the years ended March 31, 2026 and March 31, 2025 is as follows:

 

  

Number

Of

Options

  

Weighted

Average

Exercise

Price–-

Options

  

Weighted

Average

Remaining

Contractual

Life-

Options

  

Aggregate

Intrinsic

Value

(thousands)

 
                 
Options outstanding as of March 31, 2024   3,819,000   $5.50    8.3   $                   - 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Forfeited   (1,002,750)   5.50    -    - 
Options outstanding as of March 31, 2025   2,816,250   $5.50    7.2   $- 
Granted   -    -    -    - 
Exercised   -    -    -    - 
Forfeited   (561,750)   5.50    -    - 
Outstanding as of March 31, 2026   2,254,500   $5.50    6.2   $- 
Exercisable as of March 31, 2026   1,975,750   $5.50    6.1   $- 
2023 Neuro Nos Ltd Equity Incentive Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
SCHEDULE OF OPTION ACTIVITY FOR NEURONOS

A summary of the change in stock options for NeuroNos for the years ended March 31, 2026 and March 31, 2025 is as follows:

SCHEDULE OF OPTION ACTIVITY FOR NEURONOS  

  

Number

Of

Options

  

Weighted

Average

Exercise

Price–-

Options

  

Weighted

Average

Remaining

Contractual

Life-

Options

  

Aggregate

Intrinsic

Value

(thousands)

 
                 
Options outstanding as of March 31, 2024   -   $-    -   $- 
Granted   1,224,139    0.14    -    - 
Exercised   -    -    -    - 
Forfeited   -    -    -    - 
Options outstanding as of March 31, 2025   1,224,139   $0.14    9.1   $3,501 
Granted   169,913    3.00    -    - 
Exercised   -    -    -    - 
Forfeited   (134,723)   2.82    -    - 
Outstanding as of March 31, 2026   1,259,329   $0.24    8.1   $3,477 
Exercisable as of March 31, 2026   622,341   $0.19    8.1   $1,748